Decoy receptor 3 improves survival in experimental sepsis by suppressing the inflammatory response and lymphocyte apoptosis

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Liang, DongYu ^a   Hou, YanQiang ^a   Lou, XiaoLi ^a   Chen, HongWei ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 6; RECOMBINANT DECOY RECEPTOR 3 FC; RECOMBINANT RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYTOKINE; DECOY RECEPTOR 3; FAS LIGAND;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BACTERIAL CLEARANCE; CECAL LIGATION AND PUNCTURE-INDUCED SEPSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LIVER INJURY; LUNG INJURY; LYMPHOCYTE; LYMPHOCYTE COUNT; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; SURVIVAL RATE; ANIMAL; DISEASE MODEL; GENETICS; IMMUNOLOGY; LIVER; LUNG; METABOLISM; MORTALITY; PATHOLOGY; SEPSIS; SPLEEN; THYMUS;

BACTERIA (MICROORGANISMS); MUS;

ANIMALS; APOPTOSIS; CYTOKINES; DISEASE MODELS, ANIMAL; FAS LIGAND PROTEIN; LIVER; LUNG; LYMPHOCYTES; MICE; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 6B; SEPSIS; SPLEEN; THYMUS GLAND;

EID: 84938630574     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0131680     Document Type: Article

References (36)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001; 29:1303-1310. PMID: 11445675
2. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003; 348:1546-1554. PMID: 12700374
3. Bone RC. The pathogenesis of sepsis. Ann Intern Med. 1991; 115:457-64. PMID: 1872494
4. Skrupky LP, Kerby PW, Hotchkiss RS. Advances in the management of sepsis and the understanding of key immunologic defects. Anesthesiology. 2011; 115:1349-62. doi: 10.1097/ALN.0b013e31823422e8 PMID: 21952252
5. Cinel I, Dellinger RP. Advances in pathogenesis and management of sepsis. Curr Opin Infect Dis. 2007; 20:345-9. PMID: 17609592
6. Ward PA. Immunosuppression in sepsis. JAMA. 2011; 306:2618-21. doi: 10.1001/jama.2011.1831 PMID: 22187286
7. Exline MC, Justiniano S, Hollyfield JL, Berhe F, Besecker BY, Das S, et al. Microvesicular caspase-1 mediates lymphocyte apoptosis in sepsis. PLoS One. 2014; 9:e90968 doi: 10.1371/journal.pone.0090968 PMID: 24643116
8. Harjai M, Bogra J, Kohli M,Pant AB. Is suppression of apoptosis a new therapeutic target in sepsis? Anaesth Intensive Care 2013; 41:175-83. PMID: 23530784
9. Yan Z, Li J, Lou J, Zhou Y, Bo L, Zhu J, et al. Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients. Critical Care. 2011; 15:R70-9 doi: 10.1186/cc10059 PMID: 21349174
10. Ayala A, Perl M, Venet F, Lomas-Nerira J, Swan R, Chunq CS. Apoptosis in sepsis: mechanisms, clinical impact and potential therapeutic targets. Curr Pharm. 2008; 14:1853-59.
11. Manjuck J, Saha DC, Astiz M, Eales LJ, Rackow EC. Decreased response to recall antigens is associated with depressed costimulatory receptor expression in septic critically ill patients. J Lab Clin Med. 2000; 135:153-60. PMID: 10695660
12. Nolan A, Weiden M, Kelly A, Hoshino Y, Hoshino S, Mehta N, et al. CD40 and CD80/86 act synergistically to regulatate inflammation and mortality in polymicrobial sepsis. Am J Respir Crit Care Med. 2008; 177:301-08. PMID: 17989345
13. Toda M, Kawamot T, Ueha T, Kishimoto K, Hara H, Fukase N, et al. 'Decoy' and 'non-decoy' functions of DcR3 promote malignant potential in human malignant fibrous histiocytoma cells. Int J Oncol. 2013; 43:703-12. doi: 10.3892/ijo.2013.1999 PMID: 23817777
14. Chen L, Tian X, Li W, Agarwal A, Zhuang G. Expressions of Fas/DcR3 and RGD-FasL mediated apoptosis in pituitary adenomas. Neurol India. 2009; 57:28-30. PMID: 19305072
15. Havashi S, Miura Y, Nishiyama T, Mitani M, Tateishi K, Sakai Y, et al. Decoy receptor 3 expressed in rheumatoid synovial fibroblasts protects the cells against Fas-induce apoptosis. Arthritis Rheum. 2007; 56:1067-75. PMID: 17393415
16. Lin WW, Hsieh SL. Decoy receptor 3: a pleiotropic immunomodulator and biomarker for inflammatory disease, autoimmune disease and cancer. Biochem Pharmacol. 2011; 81:838-47. doi: 10.1016/j.bcp.2011.01.011 PMID: 21295012
17. Lee CS, Hu CY, Tsai HF, Wu CS, Hsieh SL, Liu LC, et al. Elevated serum decoy receptor 3 with enhanced T cell activation in systemic lupus erythematosus. Clin Exp Immunol. 2008; 151:383-90. doi: 10.1111/j.1365-2249.2007.03579.x PMID: 18190609
18. Hou YQ, Xu P, Zhang M, Han D, Peng L, Liang DY, et al. Serum decoy receptor 3, a potential new biomarker for sepsis. Clin Chim Acta. 2012; 413:744-8. doi: 10.1016/j.cca.2012.01.007 PMID: 22280900
19. Hubbard WJ, Choudhry M, Schwacha MG, Kerby JD, Rue LW, Bland KI, et al. Cecal ligation and puncture. Shock. 2005; 24:52-7. PMID: 16374373
20. Xie K, Yu Y, Pei Y, Hou L, Chen S, Xiong L, et al. Protective effects of hydrogen gas on murine polymicrobial sepsis via reducing oxidative stress and HMGB1 release. Shock. 2010; 34:90-7, doi: 10.1097/SHK.0b013e3181cdc4ae PMID: 19997046
21. Macher GS, Aulmann S, Wagener N, Funke B, Taqscherer KE, Haferkamp A, et al. Decoy receptor 3 is a prognostic factor in renal cell cancer. Neoplasia. 2008; 10:1049-56. PMID: 18813347
22. Tu HF, Liu CJ, Liu SY, Chen YP, Yu EH, Lin SH, et al. Serum decoy receptor 3 level: a predictive marker for nodal metastasis and survival among oral cavity cancer patients. Head Neck. 2011; 33:396-402. doi: 10.1002/hed.21467 PMID: 20645287
23. Chen CY, Yang KY, Chen MY, Chen HY, Lin MT, Lee YC, et al. Decoy receptor 3 levels in peripheral blood predict outcomes of acute respiratory distress syndrome. Am J Respir Crit Care Med. 2009; 180:751-60. doi: 10.1164/rccm.200902-0222OC PMID: 19644047
24. Cardinale CJ, Wei Z, Panossian S, Wang F, Kim CE, Mentch FD, et al. Targeted resequencing identifies defective variants of decoy receptor 3 in pediatric-onset inflammatory bowel disease. Genes Immun. 2013; 14:447-52. doi: 10.1038/gene.2013.43 PMID: 23965943
25. Hsu TL, Wu YY, Chang YC, Yang CY, Lai MZ, Su WB, et al. Attenuation of Th1 response in decoy receptor 3 transgenic mice. J Immunol. 2005; 175:5135-45. PMID: 16210617
26. Herzum I, Renz H. Inflammatory markers in SIRS, sepsis and septic shock. Curr Med Chem 2008; 15:581-7. PMID: 18336272
27. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care 2010; 14:R15-33. doi: 10.1186/cc8872 PMID: 20144219
28. van den Berg JW, van der Zee M, de Bruin RW, van Holten-Neelen J, Naqtzaam NM, IJzermans JN, et al. Mild vs. strong anti-inflammatory therapy during early sepsis in mice: a matter of life and death. Crit Care Med. 2011; 39:1275-81. doi: 10.1097/CCM.0b013e31820edf75 PMID: 21336123
29. Panacek EA, Marshall JC, Albertson TE, Johnson DH, Johnson S, MacArthur RD, et al. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab′)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med. 2004; 32:2173-82. PMID: 15640628
30. Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA. 2011; 306:2594-605. doi: 10.1001/jama.2011.1829 PMID: 22187279
31. Hotchkiss RS, Swanson PE, Knudson CM, Chang KC, Cobb JP, Osborne DF, et al. Overexpression of Bcl-2 in transgenic mice decreases apoptosis and improves survival in sepsis. J Immunol. 1999; 162:4148-56. PMID: 10201940
32. Matsuda N, Yamamoto S, Takano K, Kaqeyama S, Kurobe Y, Yoshihara Y, et al. Silencing of fas associated death domain protects mice from septic lung inflammation and apoptosis. Am J Respir Crit Care Med. 2009; 179:806-15. doi: 10.1164/rccm.200804-534OC PMID: 19201926
33. Yun Z, Tao ZH, Ye Tian, Zhu J, Cao L, Deng X, et al. Ginsenoside Rg1 improves survival in a murine model of polymicrobial sepsis by suppressing the inflammatory response and apoptosis of lymphocytes. Journal of Surgical Research. 2013; 183:760-766. doi: 10.1016/j.jss.2013.01.068 PMID: 23478085
34. Funke B, Autschbach F, Kim S, Lastitschka F, Strauch U, Roqler G, et al. Functional characterisation of decoy receptor 3 in Crohn's disease. Gut. 2009; 58:483-91. doi: 10.1136/gut.2008.148908 PMID: 19039087
35. Ayala A, Xu YX, Ayala CA, Sonefeld DE, Karr SM, Evans TA, et al. Increased mucosal B-lymphocyte apoptosis during polymicrobial sepsis is a Fas ligand but not an endotoxinmediated process. Blood. 1998; 91:1362-72. PMID: 9454767
36. Papathanassoglou EDE, Moynihan JA, McDermott MP, Ackerman MH. Expression of Fas (CD95) and Fas ligand on peripheral blood mononuclear cells in critical illness and association with multiorgan dysfunction severity and survival. Crit Care Med. 2001; 29;709-18. PMID: 11373453